预测β受体阻滞剂对儿童血管迷走性晕厥治疗效果的标志物：一篇综述。
Markers for predicting the efficacy of beta-blockers in vasovagal syncope management in children: A mini-review.
作者信息
Wang Jing, Liu Xueqin, Jin Hongfang, Du Junbao
机构信息
Department of Pediatrics, Peking University First Hospital, Beijing, China.
Key Laboratory of Molecular Cardiovascular Sciences, Ministry of Education, Beijing, China.
出版信息
Front Cardiovasc Med. 2023 Mar 8;10:1131967. doi: 10.3389/fcvm.2023.1131967. eCollection 2023.
Vasovagal syncope (VVS) is a common subtype of neurally mediated syncope. It is prevalent in children and adolescents, and critically affects the quality of life of patients. In recent years, the management of pediatric patients with VVS has received extensive attention, and β-blocker serves as an important choice of the drug therapy for children with VVS. However, the empirical use of β-blocker treatment has limited therapeutic efficacy in patients with VVS. Therefore, predicting the efficacy of β-blocker therapy based on biomarkers related to the pathophysiological mechanism is essential, and great progress has been made by applying these biomarkers in formulating individualized treatment plans for children with VVS. This review summarizes recent advances in predicting the effect of β-blockers in the management of VVS in children.
血管迷走性晕厥（VVS）是神经介导性晕厥的一种常见亚型。它在儿童和青少年中普遍存在，并严重影响患者的生活质量。近年来，小儿VVS的管理受到广泛关注，β受体阻滞剂是治疗小儿VVS药物治疗的重要选择。然而，β受体阻滞剂治疗的经验性应用对VVS患者的治疗效果有限。因此，基于与病理生理机制相关的生物标志物预测β受体阻滞剂治疗的疗效至关重要，并且通过将这些生物标志物应用于制定小儿VVS的个体化治疗方案已取得了很大进展。本综述总结了预测β受体阻滞剂对小儿VVS治疗效果的最新进展。
Zotero 插件